Advanced Navigated TMS Shows Promise for Combat PTSD in Military Personnel and Veterans
A groundbreaking study led by UT Health San Antonio researchers has revealed that an advanced form of transcranial magnetic stimulation (TMS), known as "navigated TMS," when combined with psychotherapy, achieved remarkable success in treating combat-related post-traumatic stress disorder (PTSD). The findings indicate clinically significant symptom reductions for 85% of active military personnel and veterans. This innovative, image-guided, robotic TMS method could emerge as an important new tool for enhancing PTSD care.
"Navigated TMS, when combined with psychotherapy, resulted in clinically significant symptom reductions for 85% of active military personnel and veterans with combat-related post-traumatic stress disorder (PTSD)."
Significant Symptom Reductions Observed
The randomized clinical trial tracked participants one month post-treatment. A striking 85% of individuals who received navigated TMS alongside psychotherapy experienced clinically significant symptom reductions. This contrasts sharply with just under 60% in a control group that received a sham TMS procedure in addition to psychotherapy.
The positive effects were also sustained over time. At a three-month follow-up, 73% of the active TMS group maintained their improvements, while less than 30% in the sham group did. Participants in the active TMS group were also notably more likely to sustain these treatment gains.
First-Ever Image-Guided TMS Trial for PTSD
The study enrolled 119 active-duty military personnel and veterans. An overwhelming 92% of these participants were diagnosed with severe or extremely severe combat-related PTSD. All individuals participated in a comprehensive 30-day residential treatment program.
This trial holds a significant distinction: it was the first reported registered clinical trial utilizing image-guided, robotic TMS delivery for any disorder. The findings were published in JAMA Network Open, under the title "Residential Therapy with Navigated TMS for Combat-Related Posttraumatic Stress Disorder: A Randomized Clinical Trial."
The Precision of Navigated TMS
The "navigated TMS" method, a technology developed and patented by Dr. Peter T. Fox, director of the Research Imaging Institute at UT Health San Antonio and the study's principal investigator, leverages MRI and robotic control. This sophisticated system precisely guides the TMS device to target specific brain areas, tailored to an individual's unique brain anatomy.
Conventional TMS, which uses an electromagnet to generate pulsing magnetic fields, typically lacks this level of personalized targeting precision. Researchers believe this enhanced precision was a key factor contributing to the positive outcomes observed in the study.
Addressing the Challenges of Combat PTSD Treatment
PTSD affects an estimated 4% to 17% of U.S. military personnel deployed to Iraq and Afghanistan. Current treatments include drug therapy and trauma-focused cognitive-behavioral therapies like prolonged exposure. However, these methods can have limitations, including potential ineffectiveness, undesirable side effects, or high dropout rates.
Combat PTSD is widely recognized as generally more challenging to treat than civilian PTSD. This difficulty has spurred researchers to explore augmented treatments, particularly combination therapies involving medical devices. While TMS is FDA-approved for major depressive disorder and obsessive-compulsive disorder, it is not yet approved for PTSD.
Future Directions and Broader Implications
The study was conducted as part of the Consortium to Alleviate PTSD (CAP), a multi-institutional network supported by funding from the Department of Defense and Department of Veterans Affairs.
Looking ahead, researchers plan further investigations into both regular and navigated TMS. Future studies are expected to explore its potential application with other cognitive-behavioral therapies, different types of PTSD patients, and in non-hospital settings, expanding the reach and understanding of this promising treatment.